IP Verse

Compounds And Methods For Treatment Of Inflammatory Bowel Disease With Extra-Intestinal Manifestations - EP3582814

The patent EP3582814 was granted to Arena Pharmaceuticals on May 1, 2024. The application was originally filed on Feb 16, 2018 under application number EP18710583A. The patent is currently recorded with a legal status of "Revoked".

EP3582814

ARENA PHARMACEUTICALS
Application Number
EP18710583A
Filing Date
Feb 16, 2018
Status
Revoked
Jun 27, 2025
Grant Date
May 1, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

TEVA PHARMACEUTICALSFeb 1, 2025VON KAUFFMANNADMISSIBLE
MAIWALDJan 31, 2025MAIWALDADMISSIBLE

Patent Citations (8) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2010011316
DESCRIPTIONWO2011094008
DESCRIPTIONWO2016209809
INTERNATIONAL-SEARCH-REPORTWO2016112075
OPPOSITIONWO2011094008
OPPOSITIONWO2016112075
OPPOSITIONWO2016209809
OPPOSITIONWO2018151834

Non-Patent Literature (NPL) Citations (9) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- Marzano Angelo V. ET AL, "Cutaneous Manifestations in Patients With Inflammatory Bowel Diseases : Pathophysiology, Clinical Features, and Therapy", HHS PUBLIC ACCESS AUTHOR MANUSCRIPT, US, vol. 20, no. 1, doi:10.1097/01.MIB.0000436959.62286.f9, ISSN 1078-0998, (20131007), pages 213 - 227, URL: https://watermark.silverchair.com/ibd0213.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAvAwggLsBgkqhkiG9w0BBwagggLdMIIC2QIBADCCAtIGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMqKYDvc6OtVbDWeFEAgEQgIICoxrTRRsb7ySgOGPSXPQlpkawAYD4CUEhtM-pgFky6OTFQUBLxaBNDnjte-grSIBRFdfwyon_q27rjl7u8V9g3s4zw9s8, XP093064796
OPPOSITION- Anonymous, "Etrasimod", WHO Drug Information; Proposed INN: List 116, World Health Organization, US, US, (20161209), vol. 30, no. 4, pages 605 - 633, XP009560048-
OPPOSITION- Arena Pharmaceuticals, "Safety and Ecacy of Etrasimod (APD334) in Patients With Ulcerative Colitis - NCT02447302", Clinical Trials, ClinicalTrials.gov, vol. 27, no. 6, doi:10.1093/oncolo/oyac035, pages 476 - 486, Clinical Trials, URL: https://clinicaltrials.gov/study/NCT02447302?term=NCT02447302&rank=1&tab=history&a=13#version-content-panel, XP093259306-
OPPOSITION- D11 - G 0002/21-
OPPOSITION- D2 - Submission during examination of EP 3 582 814 B1 dated 22 December 2021-
OPPOSITION- Marzano Angelo V., Borghi Alessandro, Stadnicki Antoni, Crosti Carlo, Cugno Massimo, "Cutaneous Manifestations in Patients With Inflammatory Bowel Diseases : Pathophysiology, Clinical Features, and Therapy", HHS PUBLIC ACCESS AUTHOR MANUSCRIPT, Lippincott Williams & Wilkins, US, US , (20131007), vol. 20, no. 1, doi:10.1097/01.MIB.0000436959.62286.f9, ISSN 1078-0998, pages 213 - 227, XP093064796
OPPOSITION- Stephan R. Vavricka, Alain Schoepfer, Michael Scharl, Peter L. Lakatos, Alexander Navarini, Gerhard Rogler, "Extraintestinal Manifestations of Inflammatory Bowel Disease :", HHS PUBLIC ACCESS AUTHOR MANUSCRIPT, Lippincott Williams & Wilkins, US, US , (20150801), vol. 21, no. 8, doi:10.1097/MIB.0000000000000392, ISSN 1078-0998, pages 1982 - 1992, XP055477312
OPPOSITION- Ruocco E, Sangiuliano S, Gravina Ag, Miranda A, Nicoletti G, "Pyoderma gangrenosum: an updated review", JEADV , The Journal of the European Academy of Dermatology and Venereology, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM., NL, NL , (20090901), vol. 23, no. 9, doi:10.1111/j.1468-3083.2009.03199.x, ISSN 0926-9959, pages 1008 - 1017, XP093259310
OPPOSITION- Yamamoto Toshiyuki, "Crohn’s Disease and Mucocutaneous Conditions", Journal of Clinical & Experimental Dermatology Research, (20110101), vol. 4, no. 2, doi:10.4172/2155-9554.S2-001, ISSN 2155-9554, XP093259312

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents